CO6270235A2 - Un peptido de proiselt seleccionado de un grupo acetilo n-terminal, amida y cisteine - Google Patents
Un peptido de proiselt seleccionado de un grupo acetilo n-terminal, amida y cisteineInfo
- Publication number
- CO6270235A2 CO6270235A2 CO10037698A CO10037698A CO6270235A2 CO 6270235 A2 CO6270235 A2 CO 6270235A2 CO 10037698 A CO10037698 A CO 10037698A CO 10037698 A CO10037698 A CO 10037698A CO 6270235 A2 CO6270235 A2 CO 6270235A2
- Authority
- CO
- Colombia
- Prior art keywords
- peptide
- modified
- mouse
- terminal
- group
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 29
- 210000004899 c-terminal region Anatomy 0.000 abstract 4
- 241000699800 Cricetinae Species 0.000 abstract 3
- 102100027361 Lithostathine-1-alpha Human genes 0.000 abstract 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 3
- 238000005457 optimization Methods 0.000 abstract 3
- 101001096072 Homo sapiens Regenerating islet-derived protein 3-gamma Proteins 0.000 abstract 2
- 101100301514 Rattus norvegicus Reg3g gene Proteins 0.000 abstract 2
- 102100037886 Regenerating islet-derived protein 3-gamma Human genes 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 101001021527 Homo sapiens Huntingtin-interacting protein 1 Proteins 0.000 abstract 1
- 101000872458 Homo sapiens Huntingtin-interacting protein 1-related protein Proteins 0.000 abstract 1
- 101000581802 Homo sapiens Lithostathine-1-alpha Proteins 0.000 abstract 1
- 101000581803 Homo sapiens Lithostathine-1-beta Proteins 0.000 abstract 1
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 abstract 1
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 abstract 1
- 102100035957 Huntingtin-interacting protein 1 Human genes 0.000 abstract 1
- 108010035620 INGAP peptide Proteins 0.000 abstract 1
- 108010014691 Lithostathine Proteins 0.000 abstract 1
- 102100027338 Lithostathine-1-beta Human genes 0.000 abstract 1
- 101100343530 Mus musculus Reg2 gene Proteins 0.000 abstract 1
- 101100412400 Mus musculus Reg3a gene Proteins 0.000 abstract 1
- 101100412402 Mus musculus Reg3b gene Proteins 0.000 abstract 1
- 101100301513 Mus musculus Reg3g gene Proteins 0.000 abstract 1
- 101100301519 Mus musculus Reg4 gene Proteins 0.000 abstract 1
- 108700012361 REG2 Proteins 0.000 abstract 1
- 101150108637 REG2 gene Proteins 0.000 abstract 1
- 108700012368 REG3B Proteins 0.000 abstract 1
- 101001035657 Rattus norvegicus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 abstract 1
- 101000976209 Rattus norvegicus Endoribonuclease ZC3H12A Proteins 0.000 abstract 1
- 101100120298 Rattus norvegicus Flot1 gene Proteins 0.000 abstract 1
- 101100412403 Rattus norvegicus Reg3b gene Proteins 0.000 abstract 1
- 101150043784 Reg3b gene Proteins 0.000 abstract 1
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 abstract 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004203 pancreatic function Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96901907P | 2007-08-30 | 2007-08-30 | |
| US97952607P | 2007-10-12 | 2007-10-12 | |
| US99196407P | 2007-12-03 | 2007-12-03 | |
| US3147908P | 2008-02-26 | 2008-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270235A2 true CO6270235A2 (es) | 2011-04-20 |
Family
ID=40084133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10037698A CO6270235A2 (es) | 2007-08-30 | 2010-04-05 | Un peptido de proiselt seleccionado de un grupo acetilo n-terminal, amida y cisteine |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8816047B2 (enExample) |
| EP (3) | EP2559700A3 (enExample) |
| JP (2) | JP2010538017A (enExample) |
| KR (1) | KR20100080519A (enExample) |
| CN (1) | CN101896499B (enExample) |
| AU (1) | AU2008292913B2 (enExample) |
| BR (1) | BRPI0815308A2 (enExample) |
| CA (1) | CA2698100C (enExample) |
| CO (1) | CO6270235A2 (enExample) |
| CY (1) | CY1116169T1 (enExample) |
| DK (1) | DK2193142T3 (enExample) |
| EA (1) | EA201000399A1 (enExample) |
| ES (1) | ES2534434T3 (enExample) |
| HR (1) | HRP20150330T1 (enExample) |
| IL (2) | IL233024A (enExample) |
| MA (1) | MA31822B1 (enExample) |
| MX (2) | MX2010002264A (enExample) |
| MY (1) | MY165889A (enExample) |
| NZ (3) | NZ583679A (enExample) |
| PL (1) | PL2193142T3 (enExample) |
| PT (1) | PT2193142E (enExample) |
| SG (1) | SG185940A1 (enExample) |
| SI (1) | SI2193142T1 (enExample) |
| WO (1) | WO2009029847A1 (enExample) |
| ZA (1) | ZA201001798B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| JP2008545712A (ja) | 2005-05-25 | 2008-12-18 | キュアーディーエム、インク． | ペプチド、その誘導体並びに類似体、及びそれらを使用する方法 |
| PT2193142E (pt) * | 2007-08-30 | 2015-04-22 | Curedm Group Holdings Llc | Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos |
| EP2679270B1 (en) * | 2011-02-24 | 2016-11-09 | Hisamitsu Pharmaceutical Co., Inc. | Glp-1 analogue composition for microneedle devices |
| MX365403B (es) | 2012-01-09 | 2019-05-31 | Serpin Pharma Llc | Peptidos y metodos para usarlos. |
| RU2480234C1 (ru) * | 2012-03-01 | 2013-04-27 | Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" | Способ профилактики и лечения нарушений углеводного и липидного обмена при метаболическом синдроме и энцефалопатии, применение тетрапептида и фармацевтическая композиция для профилактики и лечения таких нарушений |
| CN106668852B (zh) * | 2012-04-13 | 2020-12-25 | 艾棣维欣(苏州)生物制药有限公司 | 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用 |
| US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| AU2013284460A1 (en) | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| WO2014052611A1 (en) * | 2012-09-27 | 2014-04-03 | Levetan Claresa | Generation of new pancreatic beta cells |
| AU2013323476A1 (en) * | 2012-09-27 | 2015-07-30 | Claresa LEVETAN | Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| GB201220901D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| US20160039877A1 (en) * | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| US9321812B2 (en) * | 2014-03-28 | 2016-04-26 | Perle Bioscience | Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| WO2015158241A1 (en) * | 2014-04-18 | 2015-10-22 | National Institute Of Biological Sciences, Beijing | Reg3 therapeutics |
| JP6672175B2 (ja) * | 2014-05-07 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN105732793A (zh) * | 2014-12-08 | 2016-07-06 | 华东师范大学 | 一种胰再生源蛋白衍生物及其应用 |
| CN105727262B (zh) * | 2014-12-08 | 2020-08-25 | 华东师范大学 | 胰再生源蛋白在制备促进过度炎症伤口愈合的药物中的应用 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| AU2016317726B2 (en) | 2015-08-28 | 2022-05-26 | Serpin Pharma, Llc | Methods for treatment of diseases |
| EP3426678B1 (en) * | 2016-03-10 | 2025-07-02 | Shenzhen Hightide Biopharmaceutical, Ltd. | Conjugates of islet neogenesis peptides and analogs, and methods thereof |
| CN110958885B (zh) * | 2017-05-11 | 2024-03-12 | 深圳君圣泰生物技术有限公司 | 多肽化合物在治疗急性胰腺炎中的应用 |
| KR101995768B1 (ko) * | 2019-03-13 | 2019-07-03 | (주)엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
| JP7137696B2 (ja) * | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| AU2020293237A1 (en) * | 2019-06-13 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Methods for removing undesired components during multistage chromatographic processes |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN117442585B (zh) * | 2023-12-25 | 2024-03-19 | 北京爱思益普生物科技股份有限公司 | 一种靶向胰腺癌的雷公藤红素递送体及其制备方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) * | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH01137994A (ja) | 1987-08-10 | 1989-05-30 | Shionogi & Co Ltd | ｒｅｇ蛋白質 |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| FR2661187B1 (fr) * | 1990-04-20 | 1994-08-05 | Inst Nat Sante Rech Med | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| US5261752A (en) * | 1991-09-12 | 1993-11-16 | Nsk Ltd. | Bearing having passive pulser ring |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993011794A1 (en) * | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| ATE242005T1 (de) | 1994-12-21 | 2003-06-15 | Yeda Res & Dev | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes |
| US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| EP0815129B1 (en) * | 1995-02-22 | 2011-01-05 | Eastern Virginia Medical School of the Medical College of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DE19735587B4 (de) * | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
| US6311415B1 (en) * | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6713058B2 (en) * | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US20040132644A1 (en) * | 2001-10-16 | 2004-07-08 | The Procter & Gamble Company | Composition and method for treating diabetes |
| US20050148763A1 (en) * | 2002-02-01 | 2005-07-07 | Chugai Seiyaku Kabushiki Kaisha | Peg-binding pth or peg-binding pth derivative |
| US7166439B2 (en) * | 2002-03-01 | 2007-01-23 | Gmp Endotherapeutics, Inc. | Assay for anti-INGAP antibodies |
| US20030212000A1 (en) * | 2002-05-09 | 2003-11-13 | Medtronic Minimed, Inc. | Immunoprotective methods for beta cell neogenesis |
| WO2003105897A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a glp-1 compound |
| US6946151B2 (en) * | 2002-11-12 | 2005-09-20 | Ayurvedic-Life International, Llc | Therapeutic compositions |
| WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| EP2154145B1 (en) * | 2003-01-15 | 2013-04-24 | International Institute of Cancer Immunology, Inc. | Dimerized peptide |
| CA2519528C (en) * | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| WO2005035761A1 (en) * | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
| JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体 |
| EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| JP2008545712A (ja) | 2005-05-25 | 2008-12-18 | キュアーディーエム、インク． | ペプチド、その誘導体並びに類似体、及びそれらを使用する方法 |
| CA2608522A1 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Biomarkers for breast cancer |
| CN100429227C (zh) * | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin4多肽片段 |
| US20090155799A1 (en) * | 2006-03-02 | 2009-06-18 | Yusuke Nakamura | Methods for diagnosing pancreatic cancer using reg4 protein |
| US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
| PT2193142E (pt) | 2007-08-30 | 2015-04-22 | Curedm Group Holdings Llc | Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos |
| WO2009049222A1 (en) * | 2007-10-12 | 2009-04-16 | Curedm, Inc. | Compositions and methods of using the human proislet peptide receptor |
-
2008
- 2008-08-29 PT PT87989976T patent/PT2193142E/pt unknown
- 2008-08-29 CA CA2698100A patent/CA2698100C/en not_active Expired - Fee Related
- 2008-08-29 DK DK08798997.6T patent/DK2193142T3/da active
- 2008-08-29 BR BRPI0815308A patent/BRPI0815308A2/pt not_active IP Right Cessation
- 2008-08-29 KR KR1020107006933A patent/KR20100080519A/ko not_active Ceased
- 2008-08-29 PL PL08798997T patent/PL2193142T3/pl unknown
- 2008-08-29 SI SI200831410T patent/SI2193142T1/sl unknown
- 2008-08-29 SG SG2012080883A patent/SG185940A1/en unknown
- 2008-08-29 AU AU2008292913A patent/AU2008292913B2/en not_active Ceased
- 2008-08-29 EP EP20120183674 patent/EP2559700A3/en not_active Withdrawn
- 2008-08-29 MY MYPI2010000893A patent/MY165889A/en unknown
- 2008-08-29 HR HRP20150330TT patent/HRP20150330T1/hr unknown
- 2008-08-29 EA EA201000399A patent/EA201000399A1/ru unknown
- 2008-08-29 ES ES08798997.6T patent/ES2534434T3/es active Active
- 2008-08-29 EP EP08798997.6A patent/EP2193142B1/en active Active
- 2008-08-29 NZ NZ583679A patent/NZ583679A/en not_active IP Right Cessation
- 2008-08-29 EP EP12183685.2A patent/EP2570431A3/en not_active Withdrawn
- 2008-08-29 NZ NZ599756A patent/NZ599756A/xx not_active IP Right Cessation
- 2008-08-29 MX MX2010002264A patent/MX2010002264A/es active IP Right Grant
- 2008-08-29 WO PCT/US2008/074868 patent/WO2009029847A1/en not_active Ceased
- 2008-08-29 US US12/674,573 patent/US8816047B2/en not_active Expired - Fee Related
- 2008-08-29 CN CN200880114452.5A patent/CN101896499B/zh not_active Expired - Fee Related
- 2008-08-29 NZ NZ599755A patent/NZ599755A/xx not_active IP Right Cessation
- 2008-08-29 JP JP2010523166A patent/JP2010538017A/ja active Pending
- 2008-08-29 MX MX2013001304A patent/MX337147B/es unknown
-
2010
- 2010-02-25 IL IL233024A patent/IL233024A/en not_active IP Right Cessation
- 2010-02-25 IL IL204183A patent/IL204183A/en not_active IP Right Cessation
- 2010-03-12 ZA ZA2010/01798A patent/ZA201001798B/en unknown
- 2010-03-26 MA MA32722A patent/MA31822B1/fr unknown
- 2010-04-05 CO CO10037698A patent/CO6270235A2/es not_active Application Discontinuation
-
2013
- 2013-09-10 JP JP2013187508A patent/JP5960661B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-22 US US14/465,835 patent/US20150018272A1/en not_active Abandoned
-
2015
- 2015-04-07 CY CY20151100332T patent/CY1116169T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599755A (en) | Compositions and methods of using proislet peptides and analogs thereof | |
| AR053252A1 (es) | Antiuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| AR066042A1 (es) | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) | |
| AR039231A1 (es) | Agentes de union ox40r novedosos | |
| CL2008000910A1 (es) | Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide. | |
| MX2020002977A (es) | Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos. | |
| PA8738401A1 (es) | Proteinas de fusion de exendina | |
| CL2011000086A1 (es) | Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b. | |
| ES2927977T3 (es) | Moduladores peptídicos de la interacción entre el péptido C humano y el receptor de elastina humana para uso terapéutico | |
| CL2008001661A1 (es) | Proteina de fusion que comprende un peptido natriuretico y un dominio fc de un anticuerpo; molecula de acido nucleico que la codifica; composicion farmaceutica que la comprende; y su uso para tratar enfermedades asociadas con la actividad diuretica, natriuretica y vasodilatadora anomala. | |
| CY1121380T1 (el) | Γονιδιακη θεραπεια για τη νοσο νιεμann-pick τυπου a | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| MX2009012343A (es) | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. | |
| ES2422584T3 (es) | Prótesis para estimular la cinemática natural | |
| UY32883A (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
| CR11107A (es) | INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1 | |
| CL2009000829A1 (es) | Metodo para identificar un secretagogo del peptido yy (pyy) que comprende poner en contacto un compuesto de prueba con una celula huesped o con la membrana que contiene un receptor acoplado a proteina g de secuencia id no 2; determinar la capacidad estimular a este y la secresion de pyy en celula enteroendocrina de vertebrado. | |
| GT200900163A (es) | Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion. | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| BR112015024587A2 (pt) | variante de região fc | |
| EP2189471A4 (en) | FOXM1 PEPTIDE AND MEDICAMENT THEREFOR | |
| PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| NO20082345L (no) | Selektive VPAC2 reseptorpeptidagonister | |
| CL2007002931A1 (es) | Agente tensioactivo que comprende un vehiculo lipidico y una combinacion de analogo polipeptidico de la proteina tensioactiva nativa sp-c y sp-b; composicion tensioactiva y composicion farmaceutica que comprenden dicho agente; uso del agente para tra | |
| PE20221271A1 (es) | Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |